NCT07358403

Brief Summary

The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety. The main questions it aims to answer are:

  • Does dietary supplement in capsules and drinkable reduces hair loss in women and men suffering from chronic telogen effluvium or androgenetic alopecia?
  • Were the products well accepted by the subjects from their´s perspective? Researchers will compare dietary supplement in capsules and drinkable to a placebo (a look-alike substance that contains no active ingredients) to see if dietary supplements works to reduce hair loss. Participants will:
  • Take assigned diatry supplement in capsule or drinkable or a placebo every day for 6 months
  • Visit the study facility once every 3 months for evaulations
  • Keep a diary of the product use

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 4, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 26, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 26, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 14, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 22, 2026

Completed
Last Updated

January 26, 2026

Status Verified

January 1, 2026

Enrollment Period

11 months

First QC Date

January 14, 2026

Last Update Submit

January 22, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline in the hair density at 3 and 6 months

    Pictures of chosen area of the scalp are taken and the number of hairs per cm2 is counted.

    From the baseline, at 3 months and at the end of the study (6 months).

Secondary Outcomes (1)

  • Assessment of product acceptability and perceived efficacy at 3 and 6 months

    On 3 months and 6 months of product use.

Study Arms (4)

Dietary supplement capsule

EXPERIMENTAL

Dietary supplement capsule was taken by the subjects daily during 6 months

Dietary Supplement: Dietary supplement capsule use for hair loss

Dietary supplement capsule placebo

PLACEBO COMPARATOR

Dietary supplement capsule placebo was taken by the subjects daily during 6 months

Dietary Supplement: Dietary supplement capsule placebo use for hair loss

Dietary supplement drinkable

EXPERIMENTAL

Dietary supplement drinkable was taken by the subjects daily during 6 months

Dietary Supplement: Dietary supplement drinklable use for hair loss

Dietary supplement drinkable placebo

PLACEBO COMPARATOR

Dietary supplement drinkable placebo was taken by the subjects daily during 6 months

Dietary Supplement: Dietary supplement drinklable placebo

Interventions

Dietary supplement capsule use for hair loss, once a day during 6 months.

Dietary supplement capsule

Dietary supplement capsule placebo use for hair loss, once a day during 6 months.

Dietary supplement capsule placebo

Dietary supplement drinklable use for hair loss, once a day during 6 months.

Dietary supplement drinkable

Dietary supplement drinklable placebo use for hair loss, once a day during 6 months.

Dietary supplement drinkable placebo

Eligibility Criteria

Age18 Years - 62 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy female and male subjects, including at least 70% female subjects aged over 30 years old ✓ Caucasian ethnicity
  • Aged between 18 and 62 years old (extreme included)
  • % of subjects with chronic telogen effluvium (stage from 2 to 4, according to Sinclair scale for female pattern hair loss in women and modified Sinclair scale for female pattern hair loss in men)
  • % of subjects with androgenetic alopecia (AGA): female subjects Ludwig scale (score I-II) and male subjects Hamilton- Norwood scale (vertex II-III)
  • Subjects aware of the study procedures and having signed an informed consent form
  • Subjects registered with National Health Service (NHS)
  • Subjects certifying the truthfulness of the personal data disclosed to the investigator
  • Subjects able to understand the language used in the investigation and to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements
  • Commitment not to change the daily routine or the lifestyle
  • Subject informed about the study procedures and having signed the privacy policy

You may not qualify if:

  • Subjects with acute or chronic diseases able to interfere with the outcome of the study or that are considered dangerous for the subject or incompatible with the study requirements
  • Subjects participating or planning to participate in other clinical trials
  • Subjects deprived of freedom by administrative or legal decision or under guardianship
  • Subjects not able to be contacted in case of emergency
  • Subjects admitted to a health or social facility
  • Subjects planning a hospitalization during the study
  • Subjects who participated in a similar study without respecting an adequate washout period (3 months)
  • Alimentary/Eating disorders (i.e., bulimia, psychogenic eating disorders, etc.)
  • Food allergy or food intolerances
  • Impaired immune system due to i-mmunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications
  • Subjects who have any type of gastrointestinal disease or disorders (Chrons disease, colitis, irritable bowel syndrome, intestinal malabsorption)
  • Pharmacological treatment (topic or systemic) known to interfere with the tested product or having effect on metabolism (e.g.: anticoagulants, antidepressants, drugs used to lower cholesterol levels, antiviral drugs and beta-blockers)
  • Subjects having frequent stomach burn
  • Cosmetic treatment known to interfere with the tested product (e.g.: anti-hair loss shampoo, antihair loss food supplements, anti-hair loss serum) during the study and in the last 3 months before study start
  • Subjects who intends to carry out any straightening, permanent or other treatments on hair (hair botox,etc)
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Complife Italia

San Martino Siccomario, Milan, 27028, Italy

Location

MeSH Terms

Conditions

Alopecia

Interventions

Dietary Supplements

Condition Hierarchy (Ancestors)

HypotrichosisHair DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2026

First Posted

January 22, 2026

Study Start

November 4, 2024

Primary Completion

September 26, 2025

Study Completion

September 26, 2025

Last Updated

January 26, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

The results will be shared in the paper.

Locations